Missing data methods in HIV clinical trials: Regulatory guidance and alternative approachesKELLEHER, Thomas; THIRY, Alexandra; WILBER, Richard et al.Drug information journal. 2001, Vol 35, Num 4, pp 1363-1371, issn 0092-8615Article

Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week resultsMURPHY, Robert L; SANNE, Ian; CAHN, Pedro et al.AIDS (London). 2003, Vol 17, Num 18, pp 2603-2614, issn 0269-9370, 12 p.Article

Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studiesROCHE, Henri; CONTE, Pierfranco; PEREZ, Edith A et al.Breast cancer research and treatment. 2011, Vol 125, Num 3, pp 755-765, issn 0167-6806, 11 p.Article

The effects of the Roche AMPLICOR HIV-1 MONITOR® UltraSensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and the inappropriateness of cross-study comparisonsGIORDANO, Michael; KELLEHER, Thomas; COLONNO, Richard J et al.Journal of clinical virology. 2006, Vol 35, Num 4, pp 420-425, issn 1386-6532, 6 p.Article

Hepatitis C management: the challenge of dropout associated with male sex and injection drug useLOWRY, Damien J; RYAN, John D; ULLAH, Naeem et al.European journal of gastroenterology & hepatology. 2011, Vol 23, Num 1, pp 32-40, issn 0954-691X, 9 p.Article